Drugs and Devices

FDA approvals—July 11-12, 2016

On July 12, the Food and Drug Administration (FDA) approved Xiidra (lifitegrast ophthalmic solution) for the treatment of signs and symptoms of dry eye disease. Read more

 

On July 11, the FDA approved the first focused ultrasound device, ExAblate Neuro, to treat essential tremor in patients who have not responded to medication. Read more


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares